No Data
No Data
Major Shareholder Sells Thousands of Harrow Health Shares!
H.C. Wainwright Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $57
Express News | Harrow Shares Are Trading Higher on Possible Continued Strength After the Company Issued Q4 and FY24 Revenue Guidance Above Estimates Yesterday. HC Wainwright & Co. Reiterated a Buy Rating on the Stock
Reported March 17, 2025: Harrow Sees Q4 2024 Revenue $65M-$67M Vs $58.41M Est.; FY24 Revenue $198M-$200M Vs $191.18M Est.
Express News | HC Wainwright & Co. Reiterates Buy on Harrow, Maintains $57 Price Target
Harrow Analyst Ratings
Day Lily : WOW!! Truly perfection! Good for you
🩷